Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Budesonide and Ipratropium for ARDS Prevention
NCT06657079Phase 2Completed
- Sponsor
- Damanhour University
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of budesonide, ipratropium bromide in acute respiratory distress syndrome (ARDS), sponsored by Damanhour University. Started May 2024; status: completed.
02
Drugs
budesonideipratropium bromide
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06657079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657079.